Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIIb study of intermittent versus continuous hormone deprivation treatment with ELIGARD [leuprorelin] 22.5 mg 3-Month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy.

Next Previous
X
Search
Trial Profile

A phase IIIb study of intermittent versus continuous hormone deprivation treatment with ELIGARD [leuprorelin] 22.5 mg 3-Month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary) ; Bicalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ICELAND
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 11 Oct 2016 Results of a post-hoc analysis assessing clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) were presented at the 41st European Society for Medical Oncology Congress
    • 19 May 2015 Results presented at the 110th Annual Meeting of the American Urological Association.
    • 17 Apr 2013 Planned number of patients changed from 700 to 706 German Clinical Trials Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top